Nkarta

Nkarta ROCE

The Return on Capital Employed (ROCE) of Nkarta (NKTX) as of Oct 28, 2026 is -38.81 %. In the previous year, Return on Capital Employed (ROCE) was -31.42 % — a change of 23.50% (lower).

ROCE

-38.81 %

YoY

23.50%

Last updated:

In 2025, Nkarta's return on capital employed (ROCE) was -38.81 %, a 23.50% increase from the -31.42 % ROCE in the previous year.

The Nkarta ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
6.61 USD
Jan 1, 2019
87.70 USD
Jan 1, 2020
-16.04 USD
Jan 1, 2021
-34.44 USD
Jan 1, 2022
-31.96 USD
Jan 1, 2023
-48.17 USD
Jan 1, 2024
-31.42 USD
Jan 1, 2025
-38.81 USD
The Nkarta ROCE history
YEARROCEYoY
-38.81 %+23.50%
-31.42 %-34.77%
-48.17 %+50.73%
-31.96 %-7.20%
-34.44 %+114.77%
-16.04 %-118.28%
87.70 %+1,227.64%
6.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nkarta Stock analysis

What does Nkarta do? Nkarta Inc is a biopharmaceutical company based in South San Francisco, California. The company was founded in 2015 by Dr. Raphael Rousseau (CEO) to develop a groundbreaking new therapy for cancer patients. The business model of Nkarta is based on the development of novel CAR-T cell therapies. These are a special type of immunotherapy in which the patient's own immune cells are genetically modified and used to target tumor cells. Unlike conventional chemotherapy or radiation, which can also attack healthy cells, CAR-T cell therapies specifically target cancer cells while sparing the surrounding healthy tissue. Nkarta is divided into various business areas, including research and development of new therapies, manufacturing and production of CAR-T cells, and clinical trials and approval processes for broad application. One of Nkarta's key products is NKR-2, a CAR-T cell therapy based on natural killer cells. These cells have high activity against cancer cells and can respond quickly to threats. NKR-2 differentiates itself from other therapies by its ability to be effective even at low concentrations. This means that fewer cells are needed and the risk of unwanted side effects is reduced. Nkarta is also working on other projects, including NKX101, which specializes in treating solid tumors, and Voretigene Neparvovec, a gene therapy for the rare hereditary retinal disease. In 2020, Nkarta entered into a partnership with CRISPR Therapeutics to explore the joint potential of CRISPR gene editing and CAR-T cell therapy. The collaboration aims to improve the precision and effectiveness of CAR-T cell therapies and ultimately increase the chances of a cure for cancer patients. Overall, Nkarta has had an impressive success story in recent years. The company has raised several million dollars in funding and continues to expand. The groundbreaking technology of CAR-T cell therapies is promising and has the potential to have a sustainable impact on healthcare. With Nkarta at the forefront, the future could look much more hopeful for cancer patients. Nkarta is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Nkarta's Return on Capital Employed (ROCE)

Nkarta's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Nkarta's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Nkarta's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Nkarta’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Nkarta stock

Return on Capital Employed (ROCE) of Nkarta is -38.81 % in 2025.

Return on Capital Employed (ROCE) of Nkarta changed from -31.42 % to -38.81 %, representing a 23.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Nkarta since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Nkarta with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Nkarta

All Key Metrics — Nkarta